Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity

BACKGROUND: Antivirals are needed to combat the COVID-19 pandemic, which is caused by SARS-CoV-2. The clinically-proven protease inhibitor Camostat mesylate inhibits SARS-CoV-2 infection by blocking the virus-activating host cell protease TMPRSS2. However, antiviral activity of Camostat mesylate met...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:EBioMedicine
Main Authors: Hoffmann, Markus, Hofmann-Winkler, Heike, Smith, Joan C., Krüger, Nadine, Arora, Prerna, Sørensen, Lambert K., Søgaard, Ole S., Hasselstrøm, Jørgen Bo, Winkler, Michael, Hempel, Tim, Raich, Lluís, Olsson, Simon, Danov, Olga, Jonigk, Danny, Yamazoe, Takashi, Yamatsuta, Katsura, Mizuno, Hirotaka, Ludwig, Stephan, Noé, Frank, Kjolby, Mads, Braun, Armin, Sheltzer, Jason M., Pöhlmann, Stefan
פורמט: Artigo
שפה:Inglês
יצא לאור: Elsevier 2021
נושאים:
Research Paper
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7930809/
https://ncbi.nlm.nih.gov/pubmed/33676899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2021.103255
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים